OncoMatch/Clinical Trials/NCT03026140
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
Is NCT03026140 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for colon carcinoma.
Treatment: Nivolumab · Ipilimumab · Celecoxib 200mg · BMS-986253 · BMS-986016 — In this exploratory study, patients with stage 1-3 adenocarcinoma of the colon with no signs of distant metastases will be treated with short-term immunotherapy + novel IO combinations (i.e. anti-IL 8, COX2-inhibitors, anti-LAG3). This treatment will be given during the window period until surgical resection of the tumor. The duration of treatment will be in between approximately 6 and 12 weeks.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Performance status
WHO 0–1
Prior therapy
Cannot have received: immune checkpoint inhibitor
No previous treatment with immune checkpoint inhibitors targeting CTLA-4, PD-1 or PD-L1
Cannot have received: radiation therapy
No radiotherapy prior to or planned post-surgery radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify